Dr. Qu Zhican of Nanolattix Appears at ASCO to Jointly Explore New Opportunities for the Globalization of Anti-Cancer Drugs
Release time:
2025-09-01
From May 30 to June 3, 2025, one of the most influential academic events in the field of global oncology—the Annual Meeting of the American Society of Clinical Oncology (ASCO)—was grandly held in Chicago.
Dr. Qu Zhican, Chairman of Nanolattix, along with Elizabeth Wu, Head of International Business, attended this top-tier international industry conference. They engaged in in-depth exchanges with global pharmaceutical innovation leaders, clinical experts, and industry partners, jointly exploring cutting-edge technologies and development opportunities in targeted anti-cancer drugs. This effort has elevated Nanolattix international cooperation strategy to a new level.
As a representative of China’s innovative pharmaceutical companies, Nanolattix is dedicated to the innovative R&D of targeted antibody-drug conjugate (ADC) and radionuclide-drug conjugate (RDC) therapies. The company’s self-developed BioLattix biological matrix technology platform has established a comprehensive system covering drug target screening, innovative Payload toxin small molecule conjugation and chelation technology development, precise patient selection for indications, and clinical trial protocol design. Currently, more than ten ADC/RDC pipelines are under development.
Among them, the T320-ADC drug targeting multiple malignant solid tumors has successfully obtained clinical approval in China, the United States, and Australia, officially entering a new stage of global synchronous development.
During the conference, Dr. Qu Zhican held talks with representatives from multinational pharmaceutical companies, biotechnology firms, and academic institutions, showcasing Nanolattix breakthrough progress in the field of new anti-cancer drugs. They also discussed issues such as the global development of ADC drugs and preliminarily reached several international cooperation intentions.
Nanolattix will leverage the ASCO platform to vigorously promote international technological cooperation, enabling China’s original precise anti-cancer solutions to benefit patients worldwide.
Tag:
recommend News
Share
